Drug Approval | December 05, 2025
Lupin receives FDA’s tentative approval for Siponimod tablets
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Here's a development that aims to keep your blood pressure in check. Literally!
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Presbyopia, the age-related loss of near vision, could soon be treated successfully
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated
